Friday, April 26, 2024
4/26/2024
PROJECT SUMMARY / ABSTRACT – Defining a type II IL-9R Cells communicate through specific cytokine-receptor binding to mediate immune responses and inflammation. Targeting these interactions has become an effective approach to patient treatment in a growing list of diseases. Among the cytokines, IL-9 is pleiotropic and is involved in allergic and autoimmune diseases and in tumor immunity. In hematopoietic cells IL-9 signals through the IL-9Ra chain and the ¿c chain that is shared with other cytokines including IL-2, IL-4, and IL-7. Numerous reports, including our own, demonstrate the ability of IL-9 to stimulate direct effects in non-hematopoietic cells as well. Yet, the hematopoietic-restricted expression of ¿c leaves a gap in our knowledge of how IL-9 delivers a signal to non-hematopoietic cells. The related cytokine IL-4 has a type II receptor that is composed of the IL-4Ra chain and the IL-13Ra1 chain to facilitate responses in non-hematopoietic cells. In this application we provide evidence of a type II IL-9R that is proposed to function in non-hematopoietic cells. We hypothesize that on airway epithelial cells IL-9Ra can combine with IL-13Ra1 to form a type II receptor and we provide preliminary data of a physical interaction between these receptor chains. We will test this hypothesis using gene-targeted mice and both in vitro and in vivo model systems to analyze IL-9 signaling and IL-9 function in airway epithelial cells. Together, these studies will expand the paradigm of cytokine receptor biology, provide detailed insight into IL-9 effector functions, and further define how targeting cytokine receptor chains impacts immunity in the patient population.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
